search

AHIP Submits Recommendations For Reducing Prescription Drug Prices At FDA Public Meeting

posted by Policy & Regulatory Affairs

on July 18, 2017

On July 18, AHIP delivered a statement on the need for market-based solutions to address the high cost of prescription drugs at a Food and Drug Administration (FDA) public meeting. Our statement emphasized that the current prescription drug cost crisis is a direct result of actions by the pharmaceutical industry to take advantage of a broken market. We also highlighted recommendations in three areas:

  1. delivering real competition;
  2. ensuring open and honest drug pricing; and
  3. delivering value to patients.